Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
Falandry C, Debled M, Bachelot T, Delozier T, Crétin J, Romestaing P, Mille D, You B, Mauriac L, Pujade-Lauraine E, Freyer G. Falandry C, et al. Among authors: bachelot t. Breast Cancer Res Treat. 2009 Aug;116(3):501-8. doi: 10.1007/s10549-008-0229-5. Epub 2008 Nov 20. Breast Cancer Res Treat. 2009. PMID: 19020973 Clinical Trial.
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.
Higgins M, Curigliano G, Dieras V, Kuemmel S, Kunz G, Fasching PA, Campone M, Bachelot T, Krivorotko P, Chan S, Ferro A, Schwartzberg L, Gillet M, De Sousa Alves PM, Wascotte V, Lehmann FF, Goss P. Higgins M, et al. Among authors: bachelot t. Breast Cancer Res Treat. 2017 Apr;162(3):479-488. doi: 10.1007/s10549-017-4130-y. Epub 2017 Feb 7. Breast Cancer Res Treat. 2017. PMID: 28176175 Free PMC article. Clinical Trial.
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.
Lerebours F, Pulido M, Fourme E, Debled M, Becette V, Bonnefoi H, Rivera S, MacGrogan G, Mouret-Reynier MA, de Lara CT, Pierga JY, Breton-Callu C, Venat-Bouvet L, Mathoulin-Pélissier S, de la Motte Rouge T, Dalenc F, Sigal B, Bachelot T, Lemonnier J, Quenel-Tueux N. Lerebours F, et al. Among authors: bachelot t. Br J Cancer. 2020 Mar;122(6):759-765. doi: 10.1038/s41416-020-0733-x. Epub 2020 Jan 31. Br J Cancer. 2020. PMID: 32001832 Free PMC article. Clinical Trial.
Treatment strategies for breast cancer brain metastases.
Bailleux C, Eberst L, Bachelot T. Bailleux C, et al. Among authors: bachelot t. Br J Cancer. 2021 Jan;124(1):142-155. doi: 10.1038/s41416-020-01175-y. Epub 2020 Nov 30. Br J Cancer. 2021. PMID: 33250512 Free PMC article. Review.
Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.
Teinturier R, Abou Ziki R, Kassem L, Luo Y, Malbeteau L, Gherardi S, Corbo L, Bertolino P, Bachelot T, Treilleux I, Zhang CX, Le Romancer M. Teinturier R, et al. Among authors: bachelot t. Breast Cancer Res Treat. 2021 Dec;190(3):389-401. doi: 10.1007/s10549-021-06339-9. Epub 2021 Sep 24. Breast Cancer Res Treat. 2021. PMID: 34561764 Free PMC article.
326 results